EMERGENT BIOSOLUTIONS INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
EMERGENT BIOSOLUTIONS INC. (EBS) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $400.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2024-11-07
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for the quarter ending 2024-09-30 was $400.00K, a 60.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for the quarter ending 2023-09-30 was $1.00M.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2020 was $0.00.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2019 was $0.00.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2018 was -$1.30M.
- EMERGENT BIOSOLUTIONS INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2017 was -$700.00K.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 3 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 3 month as first filed | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 6 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 9 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 9 month as first filed | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $400.00K 10-Q · filed 2024-11-07 | $400.00K 10-Q · filed 2024-11-07 | |||||
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-07 | $1.00M derived: sum of 2 quarters · filed 2024-11-07 | $1.00M 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | |||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | ||||||
| 2022-09-30 | -$9.00M 10-Q · filed 2023-12-11 | -$10.90M 10-Q · filed 2022-11-09 | -$8.80M derived: sum of 2 quarters · filed 2023-12-11 | -$7.30M 10-Q · filed 2023-12-11 | -$10.30M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-09 | $600.00K 10-Q · filed 2023-08-09 | |||||
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-10 | ||||||
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-09 | $2.80M derived: sum of 2 quarters · filed 2022-11-09 | $7.20M 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-02 | -$5.50M 10-Q · filed 2022-08-02 | |||||
| 2021-03-31 | -$6.60M 10-Q · filed 2022-04-29 | ||||||
| 2020-12-31 | $0.00 10-K · filed 2021-02-19 | ||||||
| 2019-12-31 | $0.00 10-K · filed 2021-02-19 | ||||||
| 2018-12-31 | -$1.30M 10-K · filed 2021-02-19 | -$900.00K 10-K · filed 2019-02-22 | |||||
| 2017-12-31 | -$700.00K 10-K · filed 2020-02-25 | -$118.00K 10-K · filed 2018-02-23 | |||||
| 2016-12-31 | -$600.00K 10-K · filed 2019-02-22 | $1.82M 10-K · filed 2017-02-28 | |||||
| 2015-12-31 | $733.00K 10-K · filed 2018-02-23 | $748.00K 10-K · filed 2016-02-29 | |||||
| 2014-12-31 | $126.00K 10-K · filed 2017-02-28 | $124.00K 10-K · filed 2015-03-09 | |||||
| 2013-12-31 | -$227.00K 10-K · filed 2016-02-29 | ||||||
| 2012-12-31 | $139.00K 10-K · filed 2015-03-09 | ||||||
| 2011-12-31 | $556.00K 10-K · filed 2014-03-10 | ||||||
| 2010-12-31 | $398.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |